Clinical Case Reports (Mar 2019)

Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab

  • Anne Bolette Tjensvoll,
  • Maria Boge Lauvsnes,
  • Katrine Brekke Norheim,
  • Roald Omdal

DOI
https://doi.org/10.1002/ccr3.1987
Journal volume & issue
Vol. 7, no. 3
pp. 416 – 418

Abstract

Read online

Key Clinical Message A severe and persistent migrainous headache in a patient with primary Sjøgren's syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opioids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituximab. We hypothesize that brain‐resident autoreactive B cells were involved in headache pathogenesis and were eliminated by this procedure.

Keywords